Google
Trusted Resources: Education
Scientific literature and patient education texts
Non-Liver Transplant Therapies for ATTR Amyloidosis 2022
source: Amyloidosis Support Groups
year: 2022
authors: Jeffrey Zonder
summary/abstract:Non-Liver Transplant Therapies for ATTR Amyloidosis 2022 lists different medications and therapies for treating ATTR Amyloidosis, a genetic disorder characterized by abnormal deposits of a protein called transthyretin (TTR). The table is divided into 3 categories: Tetramer Stabilizers, RNA-directed Therapies, and Gene Editing Therapies. Some of the therapies listed, such as Patisiran, Tafamidis, Inotersen, and Vutrisiran have FDA approval, while others are still in development.
read more
myBinderRelated Content
-
Wild-Type Transthyretin Cardiac Amyloidosis – Mayo Clinichttps://www.youtube.com/watch?v=RnWxzRD1...
-
Heart Failure Resulting From Age-Related Cardiac Amyloid Disease Associated With Wild-Type Transthyretin: A Prospect...Background: Heart failure caused by wil...
-
New Era of Medicine: Researchers Publish First Positive Clinical Data for In Vivo Genome Editing in HumansResearchers from Intellia Therapeutics, ...
-
Webinar Presentation by Johnathan Wall on Imaging Systemic Amyloidosis (ATTR)https://www.youtube.com/watch?v=r9xeEAcJ...
-
Amyloidosis — Why Did I Have to Get All of Those Tests – ASG Webinar 4/7https://www.youtube.com/watch?v=IzC_yaqs...
-
ISA 2020 | The Value of Screening Biopsies in AL & ATTR Amyloidosishttps://www.youtube.com/watch?v=BkMgy9jd...
-
Symptom Mangement in Cardiac Amyloidosis: Back to Basics – ASG Webinar 3/11https://www.youtube.com/watch?v=K2TmwAfu...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Community Key Collaborator
Support for this landing page is provided by an independent education grant from
Translation of this platform made possible through an independent education grant from
Powered by
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
